EGFR and non-small cell lung carcinoma: Here, we report a patient with advanced NSCLC where chemotherapy and EGFR target therapy failed and who was administered bevacizumab in combination with sintilimab, a new anti‐PD‐1 antibody, which has shown antitumor effects and tolerability in preclinical in vitro and phase I clinical trials.